JCM
CLDX icon

JS Capital Management’s Celldex Therapeutics CLDX Stock Holding History

JS Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,300
Closed -$268K – 151
2020
Q4 		$268K Buy
+15,300
New +$275K 0.01% 113

Other funds holding CLDX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

JS Capital Management's CLDX Position: Q1 2021 in Review

JS Capital Management sold out of Celldex Therapeutics (CLDX) in Q1 2021, closing a stake of 15,300 shares — an estimated $268K sold.

JS Capital Management first reported a position in CLDX in Q4 2020 and held it in 1 quarter. The position peaked at $268K in Q4 2020. 115 funds tracked by Wall St. Rank hold CLDX as of Q1 2021.

  • JS Capital Management reported no remaining Celldex Therapeutics position as of Q1 2021 after selling out during the quarter.
  • JS Capital Management sold 15,300 Celldex Therapeutics shares in Q1 2021, an estimated $268K.
  • JS Capital Management first reported a position in Celldex Therapeutics in Q4 2020 and held it in 1 quarter.
  • JS Capital Management's Celldex Therapeutics position peaked at $268K in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2021.

Based on JS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.